Loading company…
Pukang develops long-acting peptide drug side chains and single-molecule PEG derivatives.
Founded in 2008 in Chengdu, China, Pukang develops peptide drug side chains and single-molecule PEG derivatives. Its products include nucleic acid drug materials, PEGS blocks and small molecule compounds. The company closed Series B+ funding in June 2024 and operates laboratories and a GMP-compliant production base. It plans to expand its R&D pipeline and build a production base of more than 200 acres.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in